A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Part of paid clinical trials in Goodyear, Arizona.

Sponsor
Regeneron Pharmaceuticals
Study ID
NCT07154290
Phase
PHASE2
Status
Recruiting

Conditions

  • Advanced/Metastatic Non-Small Cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ubamatamab — DRUG
    Administered per the protocol
  • REGN7075 — DRUG
    Administered per the protocol
  • Sarilumab — DRUG
    Administered per the protocol

Study Details

This study will evaluate two study drugs called ubamatamab and REGN7075, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), and sarilumab, to evaluate to see if it can help with immune-related side effects from ubamatamab. The study is looking at: * How well ubamatamab and REGN7075 works * The side effects that ubamatamab and REGN7075 might cause * How much ubamatamab and REGN7075 is in the blood at different times * If the body makes antibodies to ubamatamab and/or REGN7075, this may cause the ubamatamab to not work as well

Key Dates

Start date
Mar 18, 2026
Status verified
May 2026
Primary completion
Jun 24, 2030
Completion
Jun 24, 2030

Study Design

Enrollment
300 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm 1A
  • Experimental: Arm 1B
  • Experimental: Arm 1C
  • Experimental: Arm 2A
  • Experimental: Arm 2B
  • Experimental: Arm 2C

Primary Outcome Measure

Objective response as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 [ Time Frame: Up to 5 years ]

Central Contacts

Locations (5)

Find similar trials in Goodyear, AZ

Related Studies